AllianceBernstein
XENE icon

AllianceBernstein’s Xenon Pharmaceuticals XENE Stock Holding History

AllianceBernstein’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$90.8M Buy
1,562,276
+158,979
+11% +$8.83M 0.03% 424
2026
Q1 		$62.9M Sell
1,403,297
-190,517
-12% -$8.78M 0.02% 531
2025
Q4 		$71.4M Sell
1,593,814
-60,603
-4% -$2.55M 0.02% 522
2025
Q3 		$66.4M Buy
1,654,417
+135,890
+9% +$4.79M 0.02% 538
2025
Q2 		$47.5M Buy
1,518,527
+189,141
+14% +$6.17M 0.02% 613
2025
Q1 		$44.6M Sell
1,329,386
-113,794
-8% -$4.32M 0.02% 616
2024
Q4 		$56.6M Buy
1,443,180
+18,445
+1% +$763K 0.02% 559
2024
Q3 		$56.1M Sell
1,424,735
-58,431
-4% -$2.36M 0.02% 576
2024
Q2 		$57.8M Buy
1,483,166
+14,720
+1% +$588K 0.02% 561
2024
Q1 		$63.2M Sell
1,468,446
-106,122
-7% -$4.88M 0.02% 534
2023
Q4 		$72.5M Buy
1,574,568
+490,231
+45% +$17.3M 0.03% 496
2023
Q3 		$37M Buy
1,084,337
+1,018,321
+1,543% +$38.1M 0.02% 648
2023
Q2 		$2.54M Sell
66,016
-41,946
-39% -$1.67M ﹤0.01% 1769
2023
Q1 		$3.86M Buy
107,962
+51,127
+90% +$1.89M ﹤0.01% 1504
2022
Q4 		$2.24M Sell
56,835
-85,891
-60% -$3.13M ﹤0.01% 1839
2022
Q3 		$5.15M Sell
142,726
-287,234
-67% -$10.3M ﹤0.01% 1387
2022
Q2 		$13.1M Buy
429,960
+53,309
+14% +$1.61M 0.01% 1010
2022
Q1 		$11.5M Buy
376,651
+82,553
+28% +$2.47M ﹤0.01% 1147
2021
Q4 		$9.19M Buy
294,098
+30,995
+12% +$926K ﹤0.01% 1297
2021
Q3 		$4.02M Buy
263,103
+243,195
+1,222% +$4.23M ﹤0.01% 1723
2021
Q2 		$371K Buy
+19,908
New +$367K ﹤0.01% 2938

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

AllianceBernstein's XENE Position: Q2 2026 in Review

AllianceBernstein increased its Xenon Pharmaceuticals (XENE) stake by 11% in Q2 2026, buying an estimated $8.83M and bringing the position to 1,562,276 shares worth $90.8M. The position accounts for 0.03% of the portfolio, ranked #424.

AllianceBernstein first reported a position in XENE in Q2 2021 and has held it in 21 quarters since. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • AllianceBernstein held 1,562,276 shares of Xenon Pharmaceuticals worth $90.8M as of Q2 2026.
  • AllianceBernstein bought 158,979 Xenon Pharmaceuticals shares in Q2 2026, an estimated $8.83M.
  • Xenon Pharmaceuticals made up 0.03% of AllianceBernstein's portfolio in Q2 2026, its #424 holding.
  • AllianceBernstein first reported a position in Xenon Pharmaceuticals in Q2 2021 and has held it in 21 quarters since.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.